CMS “Functional Equivalence” Standard Targeted In Medicare Bills
Executive Summary
CMS would be prohibited from using the Aranesp/ Procrit "functional equivalence" decision as a precedent in future reimbursement rulings under both the House and Senate versions of the Medicare prescription drug bill
You may also be interested in...
BIO Creates Policy Chief Position, Plans Reports Justifying Biotech Prices
The Biotechnology Industry Organization is continuing to expand its reach into the health policy arena with the creation of a "chief of policy" position
BIO Creates Policy Chief Position, Plans Reports Justifying Biotech Prices
The Biotechnology Industry Organization is continuing to expand its reach into the health policy arena with the creation of a "chief of policy" position
CMS Keeps “Functional Equivalence” In 2004; Amgen Submits Aranesp Data
Amgen has submitted data to the Centers for Medicare & Medicaid Services suggesting reimbursement for Aranesp should be increased by more than 50% in the final 2004 Hospital Outpatient Prospective Payment System rule